Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0209

Congress meeting · Dr. Tomoko Quinn

02 May 2026 · Virtual · Dr. Tomoko Quinn, Hospital Sírio-Libanês · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0209—

Capture insight from this engagement

Location: Hospital Sírio-Libanês
Therapeutic area: Neurology
Country: Brazil
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Chronic migraine data

Scientific content used

CGRP class review
LMV persistence data summary

Questions raised

Is there guidance on switching from a monoclonal antibody?

Notes

Congress meeting with headache specialist at Hospital Sírio-Libanês. Discussed chronic migraine data.

Insights captured (1)

Capture insight

INS-0019High
Chronic migraine data
Chronic migraine data: interest in collaboration reported by headache specialist (BR).
Action in progress

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Connect with Clinical Development

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 2
Depth of exchange: 5
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0209

Audit history (0)

All create, update and approval events for this record

No audit events in sample data